Explore Cardiogen dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Cardiogen is a short cardiac-targeted peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology, studied for its proposed effects on cardiac tissue regeneration and age-related cardiac function. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting Cardiogen.
Cardiogen is one of the cardiac-targeted entries in the broader "short peptides of bioregulation" program developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson program — which also produced Epithalon, Vilon, Thymalin, Cortexin, and dozens of other organ-system-specific bioregulator peptides — is built on a unifying hypothesis that short peptides extracted from animal organ tissue act as epigenetic regulators that restore organ-specific gene expression patterns disrupted by aging. Cardiogen sits in the cardiac-tropic branch of that program and is positioned in the Russian literature as a regenerative agent for age-associated cardiac tissue dysfunction.
Cardiogen is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson short-peptide bioregulator program, sourced for cardiac and cardiovascular-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and its sequence is the parent scaffold that Cartalax and Livagen each vary by a single residue.
The Khavinson group has proposed that short peptides such as Cardiogen act through direct binding to gene-promoter DNA in cardiomyocytes, selectively modulating transcription of genes involved in connective-tissue homeostasis, antioxidant defense, and contractile-protein turnover. This mechanism is unconventional and remains poorly characterized outside the originating laboratory.
Russian observational and small comparative studies have been published in age-related cardiac decline and post-infarct rehabilitation, reporting improvements in ejection fraction and exercise tolerance versus standard care. These studies are not blinded or placebo-controlled and have not been replicated outside Russia. No Western Phase 2/3 trial has been registered.
Cardiogen has a reported half-life of ~few hours (bioregulator estimate), and the dose intervals researchers model most often fall around once daily. Short plasma half-life with daily dosing means no meaningful systemic buildup. Bioregulator effects are thought to be epigenetic and to persist beyond the dosing course rather than scale with plasma level. It is catalogued under Anti-Aging Peptides on WPA.
120 Cardiogen reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (39 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (102 sessions). The most common dosing frequency is daily (7x/week) (12 logged protocols), followed by once weekly (2).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.